New course on the 505(b)(2) application for marketing approval in the USA
A 505(b)(2) New Drug Application (NDA) is a submission to the Food and Drug Administration (FDA) for approval to market a drug in the USA. It differs from a ‘stand-alone’ NDA in that some of the data on which the applicant relies to demonstrate safety and efficacy have been obtained from publicly available sources rather […]
New course on the 505(b)(2) application for marketing approval in the USA Read More »